The EU's CHMP has granted a positive opinion on expanding the approved indications for Janssen Pharmaceuticals Inc./Genmab AS's anti-CD38 monoclonal antibody Darzalex (daratumumab; licensed from Genmab) for use in combination with lenalidomide (Celgene's Revlimid) and dexamethasone, or bortezomib (Velcade)and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.
The product was originally granted a conditional approval last May by the European Commission for use as a monotherapy for...






